Physician profile
Kaitlin E Ross
NPI 1326468786
$2,124.09
in general payments reported to CMS, 2019-2025
26 companies · $678 in 2025
The $678 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $41.33 · 2023: $764 · 2024: $640 · 2025: $678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,021 · Education: $61.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,020.81 |
| Education | $61.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $540.76 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $297.67 | 2022-2025 | Arexvy, Shingrix |
| Pfizer INC. | $197.13 | 2023-2025 | |
| Astellas Pharma US INC | $119.94 | 2023-2024 | Veozah |
| Averitas Pharma INC. | $97.77 | 2024 | Qutenza |
| Tandem Diabetes Care, INC. | $89.28 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $87.54 | 2024-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $61.26 | 2025 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $60.98 | 2024-2025 | Gvoke Hypopen |
| Corcept Therapeutics | $57.96 | 2025 | Korlym |
| Lilly USA, LLC | $57.53 | 2023-2024 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $47.26 | 2023-2024 | Ubrelvy |
| Exact Sciences Corporation | $45.92 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Inspire Medical Systems, INC. | $44.12 | 2025 | Inspire |
| Dexcom, INC. | $40.39 | 2024 | Dexcom G6 Transmitter |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $35.01 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $34.50 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.90 | 2024 | |
| Dynavax Technologies Corporation | $28.32 | 2025 | Heplisav-B |
| Recordati_rare_diseases_inc. | $26.31 | 2025 | Isturisa |
| Sumitomo Pharma America, INC. | $24.91 | 2025 | Gemtesa |
| Ibsa Pharma INC. | $23.50 | 2025 | Flector, Licart, Tirosint |
| Exeltis, USA INC. | $19.76 | 2023 | Slynd |
| Sequel Med Tech, LLC | $18.79 | 2025 | Twiist |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.96 | 2024 | Synjardy, Jardiance |
| Astrazeneca Pharmaceuticals LP | $16.62 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaitlin Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.